Another bispecific, humanized IgG1 antibody that is under investigation is zenocutuzumab (MCLA-128), which functions by way of two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 capabilities via a ‘dock and block’ system whereby a single arm on the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/